.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Boehringer Ingelheim
Johnson and Johnson
Healthtrust
US Department of Justice
Chubb
Julphar
AstraZeneca
Chinese Patent Office
Teva

Generated: November 20, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,767,097

« Back to Dashboard

Summary for Patent: 5,767,097

Title: Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
Abstract:Ribavirin is administered to a patient in a dosage range which is effective to modulate lymphokine expression in activated T cells. In particular, ribavirin is used to suppress Th2-mediated T cell responses and promote Th1-mediated T cell response. Thus, instead of administering ribavirin in its well-recognized role as an anti-viral agent, ribavirin is herein used in the treatment of imbalances in lymphokine expression. Such imbalances may be found to be concomitants of allergic atopic disorders such as allergic asthma and atopic dermatitis, helminth infection and leishmaniasis, and various primary and secondary immunodeficiencies, which may or may not also be associated with viral infection.
Inventor(s): Tam; Robert C. (Costa Mesa, CA)
Assignee: ICN Pharmaceuticals, Inc. (Costa Mesa, CA)
Application Number:08/590,449
Patent Claim Types:
see list of patent claims
Use;

No matches for this query

International Patent Family for Patent: 5,767,097

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Hungary0002452► Subscribe
Hungary0002453► Subscribe
Israel125088► Subscribe
Israel137392► Subscribe
Israel137390► Subscribe
Israel130497► Subscribe
Israel129118► Subscribe
Norway20004326► Subscribe
Norway993439► Subscribe
Norway991784► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Boehringer Ingelheim
US Department of Justice
AstraZeneca
Dow
Queensland Health
McKesson
Medtronic
QuintilesIMS
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot